Oncotarget
The cover for issue 32 of Oncotarget features Figure 2, "This figure depicts overall survival and local in-brain recurrence-free survival in the study’s subgroups," by Hussein, et al.
Survival after resection of brain metastases with white light microscopy versus fluorescence-guidance: A matched cohort analysis of the Metastasys study data |
https://doi.org/10.18632/oncotarget.27688 Abdelhalim Hussein, Veit Rohde, Christina Wolfert, Silvia Hernandez-Duran, Ingo Fiss, Annalen Bleckmann, Alonso Barrantes Freer, Dorothee Mielke, and Bawarjan Schatlo |
3026-3034 |
Abstract | PDF | Full Text | How to cite | Press Release | Order a Reprint |
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL |
https://doi.org/10.18632/oncotarget.27691 Yaya Chu, Aradhana Awasthi, Sanghoon Lee, Dina Edani, Changhong Yin, Jessica Hochberg, Tishi Shah, Tae-Hoon Chung, Janet Ayello, Carmella van de Ven, Christian Klein, Dean Lee, and Mitchell S. Cairo |
3035-3047 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Order a Reprint |
Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
https://doi.org/10.18632/oncotarget.27694 Leandro E. Mainetti, María José Rico, Cintia Daniela Kaufman, Monica Carolina Grillo, Julian Guercetti, María Virginia Baglioni, Antonela Del Giúdice, Maria Celeste Capitani, Matias Fusini, Viviana Rosa Rozados, and O. Graciela Scharovsky |
3048-3060 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Order a Reprint |
Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients |
https://doi.org/10.18632/oncotarget.27695 Aman Chauhan, Riham El-Khouli, Timothy Waits, Rohitashva Agrawal, Fariha Siddiqui, Zachary Tarter, Millicent Horn, Heidi Weiss, Elizabeth Oates, B. Mark Evers, and Lowell Anthony |
3061-3068 |
Abstract | PDF | Full Text | How to cite | Order a Reprint |
Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells |
https://doi.org/10.18632/oncotarget.27697 Rachael A. Clark, Sora Lee, Jingbo Qiao, and Dai H. Chung |
3069-3077 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Order a Reprint |
Important players in carcinogenesis as potential targets in cancer therapy: an update |
https://doi.org/10.18632/oncotarget.27689 Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, and Dariusz Pawlak |
3078-3101 |
Abstract | PDF | Full Text | How to cite | Order a Reprint |
Correction: LRP6 promotes invasion and metastasis of colorectal cancer through cytoskeleton dynamics |
https://doi.org/10.18632/oncotarget.27710 Qian Yao, Yu An, Wei Hou, Ya-Nan Cao, Meng-Fei Yao, Ning-Ning Ma, Lin Hou, Hong Zhang, Hai-Jing Liu, and Bo Zhang |
3102-3102 |
Correction | PDF | How to cite |
Correction: Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells |
https://doi.org/10.18632/oncotarget.27597 Sham S. Kakar, Seema Parte, Kelsey Carter, Irving G. Joshua, Christopher Worth, Pranela Rameshwar, and Mariusz Z. Ratajczak |
3103-3104 |
Correction | PDF | How to cite |
Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC